When was cf discovered

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 17, 2026

Quick Answer: Cystic fibrosis (CF) was first described in 1938 by Dr. Dorothy Andersen, who identified it as a distinct disease after examining lung and pancreas tissues from deceased children. The genetic mutation responsible for CF was discovered in 1989 by a team led by Lap-Chee Tsui and John Riordan at the Hospital for Sick Children in Toronto.

Key Facts

Cystic fibrosis was first identified as a distinct medical condition in 1938 by Dr. Dorothy Andersen.
Dr. Andersen published her findings in the American Journal of Diseases of Children in 1938.
The term 'cystic fibrosis' refers to the fibrous cysts observed in the pancreas of affected patients.
In 1989, researchers discovered the defective gene responsible for CF: the CFTR gene on chromosome 7.
The average life expectancy for people with CF has increased from 10 years in the 1960s to over 50 years today.

Overview

Cystic fibrosis (CF) is a genetic disorder that affects the lungs, pancreas, and other organs by causing thick, sticky mucus buildup. Though symptoms were observed earlier, CF was not recognized as a distinct disease until the 20th century.

Dr. Dorothy Andersen is credited with the first definitive description of CF in 1938 after analyzing autopsy tissues from children who died of undiagnosed respiratory and digestive conditions. Her work laid the foundation for future research and treatment.

In 1938, Dr. Dorothy Andersen published the first comprehensive clinical description of cystic fibrosis, distinguishing it from celiac disease and tuberculosis.
She coined the term 'cystic fibrosis of the pancreas' based on the fibrous scarring and cysts she observed in pancreatic tissue during autopsies.
Prior to Andersen’s work, children with CF often died in infancy and were misdiagnosed with diseases like malnutrition or asthma.
The discovery allowed for earlier diagnosis and the development of sweat tests, which became the standard diagnostic tool by the 1950s.
Andersen’s research was pivotal in establishing CF as a genetic condition, leading to decades of further study into its molecular basis.

How It Works

Understanding cystic fibrosis requires knowledge of its biological mechanisms and genetic inheritance pattern. The disease stems from mutations in a single gene but affects multiple organ systems.

CFTR Gene: The cystic fibrosis transmembrane conductance regulator (CFTR) gene, located on chromosome 7, was identified in 1989 after years of research.
Chloride Ion Transport: The CFTR protein regulates chloride flow across cell membranes; mutations disrupt this process, leading to thick mucus in organs.
Autosomal Recessive Inheritance: A person must inherit two defective copies of the CFTR gene (one from each parent) to develop CF.
Over 2,000 Mutations: More than 2,000 variants of the CFTR gene have been identified, with F508del being the most common, affecting ~70% of patients.
Sweat Chloride Test: This diagnostic method measures elevated chloride levels in sweat, with readings above 60 mmol/L confirming CF in symptomatic individuals.
Organ Impact: The lungs and pancreas are most affected, but CF also damages the liver, intestines, and reproductive system due to mucus accumulation.

Comparison at a Glance

Key milestones in the history and treatment of cystic fibrosis compared over time:

Milestone	Year	Significance
First Clinical Description	1938	Dr. Dorothy Andersen defines CF as a unique disease entity.
Sweat Test Developed	1959	Dr. Robert Gibson and Dr. Paul Farber create a reliable diagnostic method.
CFTR Gene Discovered	1989	Team led by Lap-Chee Tsui identifies the defective gene on chromosome 7.
First CF Newborn Screening	2000s	Early detection improves outcomes; now routine in all 50 U.S. states.
Trikafta Approval	2019	Modulator therapy improves lung function in ~90% of CF patients.

This timeline highlights how medical understanding evolved from clinical observation to genetic therapy. Each breakthrough improved life expectancy and quality of life for patients.

Why It Matters

The discovery and ongoing research into cystic fibrosis have had profound implications for genetics, pediatrics, and chronic disease management. CF serves as a model for understanding inherited disorders and developing targeted therapies.

Life Expectancy Growth: Median survival has risen from 10 years in the 1960s to over 50 years today due to improved care and drugs.
Genetic Screening: CF is included in routine newborn screening, allowing early intervention and better long-term outcomes.
Personalized Medicine: Drugs like Trikafta target specific mutations, marking a shift toward individualized treatment plans.
Research Model: CF research pioneered gene therapy and modulator drug development, influencing other genetic disease studies.
Global Impact: Over 70,000 people worldwide live with CF, primarily in North America and Europe.
Family Planning: Carrier screening helps couples understand their risk of having a child with CF, supporting informed reproductive decisions.

From its initial discovery to modern therapies, the journey of CF research underscores the importance of persistent scientific inquiry and patient advocacy in transforming a fatal diagnosis into a manageable condition.